SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
Curis (NASDAQ: CRIS) is the product of a three-way merger in 2000 of Pappas Capital portfolio company Reprogenesis with Creative Biomolecules and Ontogeny. The company was initially focused on regenerative medicine, but has evolved to become a leader in targeting signaling pathways – especially those involved in different cancers. The company’s so-called Hedgehog pathway inhibitor vismodegib is now being marketed in collaboration with Genentech.
Curis
Lexington, MA
NASDAQ
CRIS
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.